Floatz logo

FALLYPRIDE

Lymphoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
65/ 100

Competitive context

242 Active assets in the Lymphoma cohort.

Asset / SponsorPhaseRating
VINBLASTINE
Intensity Therapeutics, Inc.
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
The Lymphoma Academic Research Organisation
Phase 4BBB
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
BLEOMYCIN
Shandong Provincial Hospital
Phase 4BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
City of Hope Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

FALLYPRIDE is also rated in:

Alzheimer DementiaDormant
BB
Indicative ·
67 / 100
View asset →
Essential TremorDormant
BB
Indicative ·
64 / 100
View asset →
Breast CancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →